Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Intellia Therapeutics, Inc. (NASDAQ: NTLA).

Full DD Report for NTLA

You must become a subscriber to view this report.


Recent News from (NASDAQ: NTLA)

Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting
CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, and its research collaborator , Ospedale San Raffaele (OSR), presented at the 21 st Annu...
Source: GlobeNewswire
Date: May, 17 2018 07:30
Bluebird Bio: Gene Therapy Best In Class
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two...
Source: SeekingAlpha
Date: May, 16 2018 11:31
Genomic Medicine: Catch The Gene Therapy Wave
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project “HGP” this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for...
Source: SeekingAlpha
Date: May, 14 2018 15:12
New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics
CAMBRIDGE, Mass., May 14, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced new scientific advisors in immuno-oncology and autoimmunity. The advisors hail f...
Source: GlobeNewswire
Date: May, 14 2018 07:30
Next-generation CRISPR gene editing technology on the way
ScienceDaily reports that researchers at the Joint Institute of Metrology and Biology, a collaboration between Stanford University and the National Institute of Standards and Technology,  have developed a new CRISPR platform called MAGESTIC ("multiplexed accurate genome editing with s...
Source: SeekingAlpha
Date: May, 11 2018 09:44
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ...
Source: SeekingAlpha
Date: May, 09 2018 05:37
Intellia Therapeutics - Buy The Pullback?
Introduction Many investors, especially those in biotech, are familiar with clustered regularly interspaced short palindromic repeats – better known as “CRISPR”. So what is CRISPR? In short, it’s a new method to edit DNA that is much more efficient method in ter...
Source: SeekingAlpha
Date: May, 07 2018 10:59
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18
Intellia up 8% premarket after CRISPR/Cas9 patent arguments
Intellia Therapeutics (NASDAQ: NTLA ) is up  8%  premarket on light volume after the conclusion of arguments in an appeals court hearing over the ownership of CRISPR/Cas9 gene editing technology being disputed between UC-Berkeley and the Broad Institute of Technology in Boston. M...
Source: SeekingAlpha
Date: May, 01 2018 07:59
Intellia Therapeutics beats by $0.07, beats on revenue
Intellia Therapeutics (NASDAQ: NTLA ): Q1 EPS of -$0.51 beats by $0.07 . Revenue of $7.47M (+20.3% Y/Y) beats by $1.2M . Shares +7.8% PM. Press Release More news on: Intellia Therapeutics, Earnings news and commentary, Stocks on the move, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 01 2018 07:42

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1826.0024.8426.3824.26011,115,186
2018-05-1725.2025.9826.0024.67997,368
2018-05-1625.1325.2925.8024.69870,231
2018-05-1525.8025.2925.8024.271,513,557
2018-05-1423.9924.5925.295323.80951,685

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-18225,120373,78560.2271Short
2018-05-17200,658363,89555.1417Short
2018-05-16187,415303,63361.7242Short
2018-05-15385,527553,71469.6257Short
2018-05-14232,727398,26558.4352Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NTLA.


About Intellia Therapeutics, Inc. (NASDAQ: NTLA)

Logo for Intellia Therapeutics, Inc. (NASDAQ: NTLA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,022,952,089 - 05/11/2018
  • Issue and Outstanding: 43,089,810 - 04/27/2018

 


Recent Filings from (NASDAQ: NTLA)

Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 14 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: NTLA)

Daily Technical Chart for (NASDAQ: NTLA)


Stay tuned for daily updates and more on (NASDAQ: NTLA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NTLA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NTLA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of NTLA and does not buy, sell, or trade any shares of NTLA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/